According to the research report titled ‘Global Multiple Sclerosis (MS) Market - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global multiple sclerosis market was valued at USD 26.01 billion in 2020 and is expected to observe substantial growth through 2026.

The rising development of disease-modifying medications as a therapeutic option is a major driver propelling the global multiple sclerosis market. Technological advancements include the development of immuno-modulators, innovative monoclonal bodies, immunosuppressants, and interferons for the effective treatment of multiple sclerosis is also favoring the overall market scenario.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4489504/   

The growth of the industry is also driven by a shift in consumer preference toward oral drugs, and an increasing prevalence of pipeline drugs. Governmental and non-governmental organizations are encouraging the expansion of programs aimed at enhancing the quality of life for those who have the disease, thus contributing towards the overall market growth as well.

Based on the drug class, the market is divided into interferons, immunosuppressants, immunomodulators, and others. Moving onto the route of administration, global multiple sclerosis industry is fragmented into intravenous, injectable, and oral.

In terms of distribution channels, this business sphere is segmented into online pharmacy, retail pharmacy, and hospital pharmacy.

The geographical scope of this marketplace extends to the Middle East and Africa, Asia Pacific, Europe, North America, and Latin America, with major emphasis on countries such as China, Japan, France, the U.K., Germany, the U.S., Canada, Italy, India, and South Korea.

NervGen Pharma, EMD Serono Inc., Biogen Inc., Bayer AG, Teva Pharmaceuticals Industries Limited, Novartis AG, GSK plc, Pfizer Inc., F. Hoffmann-La Roche AG, and The Bristol-Myers Squibb Company are the leading companies operating in global multiple sclerosis market. 

These companies are making heavy R&D investments as well as focusing on strategic acquisitions and mergers to gain a competitive lead in this business space. Moreover, clinical studies are being conducted by these renowned pharmaceutical firms to discover innovative and efficient multiple sclerosis treatments.